Erenumab + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stable Angina
Conditions
Stable Angina
Trial Timeline
Nov 23, 2015 → Apr 13, 2017
NCT ID
NCT02575833About Erenumab + Placebo
Erenumab + Placebo is a phase 2 stage product being developed by Amgen for Stable Angina. The current trial status is completed. This product is registered under clinical trial identifier NCT02575833. Target conditions include Stable Angina.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04252742 | Approved | Completed |
| NCT03812224 | Phase 3 | Completed |
| NCT02575833 | Phase 2 | Completed |
| NCT02483585 | Phase 3 | Completed |
| NCT02456740 | Phase 3 | Completed |
| NCT02066415 | Phase 2 | Completed |
| NCT01890109 | Phase 1 | Completed |
| NCT01723514 | Phase 1 | Completed |
| NCT01688739 | Phase 1 | Completed |
Competing Products
20 competing products in Stable Angina